Kawada Natsuko, Tanaka Sachiko, Uehara Hiroyuki, Katayama Kazuhiro, Hosoki Takuya, Takami Motohisa, Tomita Yasuhiko
Hepatogastroenterology. 2014 Mar-Apr;61(130):480-3.
BACKGROUND/AIM: We evaluated the usefulness of ultrasound-elastography (US-elastography) for prediction of therapy effect by measuring strain ratio (SR).
Consecutive patients with resectable pancreatic ductal carcinoma who underwent US-elastography before and after neoadjuvant chemoradiation were included. Patients were classified into either response group or non-response group according to the histological evaluation of resected specimens. Serum carbohydrate antigen 19-9 (CA19-9), SR, and maximum standard uptake value (SUVmax) obtained from 18F-fuluoro-deoxy-D-glucose positron emission tomography and computerized tomography were measured before and after chemoradiation. Alteration rate of each parameter was compared between response group and non-response group.
Seven patients met the inclusion criteria. One patient was excluded from pancreatectomy because liver metastasis was found by laparotomy. Serum CA19-9 was not elevated for 2 patients throughout the chemoradiation. Three patients were classified into response group and the remaining three into non-response group. Alteration rate of CA19-9 and SR was shown to be grater in response group (26.83 +/- 19.69 vs. 4.87 +/- 4.25, and 3.61 +/- 2.40 vs. 1.39 +/- 0.20, respectively), whereas that of SUVmax was not (1.56 +/- 0.43 vs. 2.11 +/- 0.10).
Increase rate of SR may predict the therapy effect of neoadjuvant chemoradiation for patients with pancreatic ductal carcinoma, especially for patients without elevation of tumor markers.
背景/目的:我们通过测量应变率(SR)评估超声弹性成像(US弹性成像)对治疗效果预测的有用性。
纳入连续的可切除性胰腺导管癌患者,这些患者在新辅助放化疗前后接受了US弹性成像检查。根据切除标本的组织学评估,将患者分为反应组或无反应组。在放化疗前后测量血清糖类抗原19-9(CA19-9)、SR以及从18F-氟脱氧-D-葡萄糖正电子发射断层扫描和计算机断层扫描获得的最大标准摄取值(SUVmax)。比较反应组和无反应组各参数的变化率。
7例患者符合纳入标准。1例患者因剖腹手术发现肝转移而被排除在胰腺切除术之外。2例患者在整个放化疗过程中血清CA19-9未升高。3例患者被分为反应组,其余3例分为无反应组。反应组CA19-9和SR的变化率更高(分别为26.83±19.69对4.87±4.25,以及3.61±2.40对1.39±0.20),而SUVmax的变化率则不然(1.56±0.43对2.11±0.10)。
SR的升高率可能预测胰腺导管癌患者新辅助放化疗的治疗效果,特别是对于肿瘤标志物未升高的患者。